Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of GoodwillAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Depreciation and Depletion (2016 - 2025)

Avanos Medical's Depreciation and Depletion history spans 12 years, with the latest figure at $4.7 million for Q4 2024.

  • For Q4 2024, Depreciation and Depletion changed N/A year-over-year to $4.7 million; the TTM value through Dec 2024 reached $20.3 million, changed N/A, while the annual FY2025 figure was $19.7 million, 2.96% down from the prior year.
  • Depreciation and Depletion for Q4 2024 was $4.7 million at Avanos Medical, down from $5.3 million in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $6.0 million in Q4 2020 and bottomed at $3.4 million in Q2 2022.
  • The 5-year median for Depreciation and Depletion is $5.4 million (2021), against an average of $5.2 million.
  • The largest annual shift saw Depreciation and Depletion soared 65.71% in 2020 before it tumbled 37.04% in 2022.
  • A 5-year view of Depreciation and Depletion shows it stood at $6.0 million in 2020, then decreased by 11.67% to $5.3 million in 2021, then decreased by 20.75% to $4.2 million in 2022, then surged by 38.1% to $5.8 million in 2023, then decreased by 18.97% to $4.7 million in 2024.
  • Per Business Quant, the three most recent readings for AVNS's Depreciation and Depletion are $4.7 million (Q4 2024), $5.3 million (Q3 2024), and $5.0 million (Q2 2024).